HIV and diabetes intersect through several routes: antiretroviral therapy effects, chronic inflammation, lipodystrophy, and hepatitis C co-infection. People living with HIV face approximately 4 times the type 2 diabetes risk of the general population. Modern integrase inhibitor regimens are far safer metabolically than older protease inhibitor regimens, but weight gain on newer drugs and tenofovir kidney effects still require attention.
Why HIV Raises Diabetes Risk
- Antiretroviral therapy — older drugs strongly diabetogenic, newer ones safer
- Chronic immune activation and inflammation, even with virologic suppression
- Lipodystrophy — fat redistribution affects insulin sensitivity
- Hepatitis C co-infection — independently raises diabetes risk
- Aging HIV population — accumulation of traditional risk factors
- Weight gain on modern regimens
Relative Risk in Numbers
| Group | Approximate Type 2 Diabetes Risk |
|---|---|
| General population | Baseline |
| People with HIV — overall | ~4 times higher |
| HIV + older protease inhibitor regimen | Substantially higher |
| HIV + modern integrase inhibitor regimen | Lower than older regimens but still elevated |
| HIV + hepatitis C co-infection | Compounded risk |
Antiretroviral Therapy and Metabolic Effects
- Older protease inhibitors (lopinavir, atazanavir, indinavir) — strongly diabetogenic; cause insulin resistance
- Newer protease inhibitors (darunavir) — less metabolic impact but not neutral
- Older NRTIs (didanosine, stavudine) — mitochondrial toxicity, lipoatrophy, diabetes risk; rarely used now
- Tenofovir disoproxil fumarate (TDF) — kidney effects matter for metformin dosing; weight-neutral or slight loss
- Tenofovir alafenamide (TAF) — easier on kidneys but weight gain more common
- Integrase strand transfer inhibitors (raltegravir, dolutegravir, bictegravir, elvitegravir) — weight gain prominent with dolutegravir and bictegravir; modest diabetes risk through weight
- NNRTIs (efavirenz, rilpivirine, doravirine) — generally metabolically neutral; efavirenz can raise lipids
- Long-acting injectable (cabotegravir + rilpivirine) — limited long-term metabolic data
Lipodystrophy
- Fat loss (lipoatrophy) — face, arms, legs, buttocks; most common with older NRTIs
- Fat accumulation (lipohypertrophy) — abdomen, dorsocervical pad (“buffalo hump”), breasts
- Mixed pattern often present
- Insulin resistance and dyslipidemia common
- Tesamorelin (Egrifta) approved for excess abdominal fat in HIV
- Switching from older to newer regimens can partially reverse lipoatrophy
Diabetes Medications in HIV
- Metformin — first-line; dose reduce if eGFR 30 to 45; avoid if eGFR less than 30; monitor B12
- SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) — caution with recurrent UTIs and genital infections; monitor for euglycemic DKA, particularly in patients on ART that affects weight
- GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) — weight loss helps offset ART-related weight gain
- DPP-4 inhibitors (sitagliptin, linagliptin) — generally safe; modest A1C effect
- Sulfonylureas — hypoglycemia risk; lower priority
- Pioglitazone — improves insulin sensitivity but can worsen lipohypertrophy; weight gain
- Insulin — used as needed for type 1 or advanced type 2; some drug-drug interactions are minimal
Drug-Drug Interactions to Watch
- Statins — pravastatin and rosuvastatin generally safer with ART than simvastatin; ritonavir-boosted regimens require dose attention
- Glucocorticoids — ritonavir boosts levels and can cause iatrogenic Cushing’s syndrome
- Pioglitazone — interactions modest with most ART
- Metformin — limited interaction concern aside from kidney function
- Sulfonylureas — limited interaction concern
- SGLT2 inhibitors and GLP-1 receptor agonists — generally minimal interactions
Cardiovascular and Renal Considerations
- HIV independently raises cardiovascular risk by roughly 1.5 to 2 times
- Combined with diabetes, statins are typically started earlier
- Aspirin therapy considered based on overall risk score
- Tenofovir disoproxil fumarate can impair kidneys — monitor eGFR and urine protein
- SGLT2 inhibitors offer renal and cardiovascular benefit in diabetes + chronic kidney disease
- Blood pressure target generally under 130/80 mm Hg in diabetes + cardiovascular risk
Hepatitis Co-Infection
- Hepatitis C co-infection independently raises diabetes risk
- Direct-acting antivirals (DAAs) for HCV — sofosbuvir-based, glecaprevir/pibrentasvir — can improve glucose after cure
- Hepatitis B vaccination recommended for all adults with diabetes
- Coinfected patients need liver-aware diabetes regimens
- See our companion article on hepatitis and diabetes
HIV Testing in New Diabetes
- Universal HIV testing is recommended at least once for all adults
- New diabetes plus HIV risk factors (men who have sex with men, multiple partners, IV drug use, partner with HIV) — offer testing
- Unexplained weight loss with new diabetes — broader workup including HIV
- Lipodystrophy pattern on examination is a clue
- Pre-exposure prophylaxis (PrEP) does not cause diabetes
Vaccination and Infection
- Pneumococcal vaccine series — strongly recommended
- Annual influenza vaccine
- Hepatitis B vaccine for all adults with diabetes (ADA recommendation)
- Hepatitis A vaccine for those at risk
- Shingles (recombinant zoster) for adults 50 and older with HIV regardless of CD4
- HPV vaccine for those eligible
- COVID-19 boosters per current guidelines
- Live vaccines avoided when CD4 below 200
Related Reading
See our overview of complications and related conditions and resources on treatment. Related infectious-disease overlaps include hepatitis, and other comorbid disease guides include IBD and celiac disease.
The Bottom Line
People with HIV have roughly 4 times the type 2 diabetes risk of the general population. Older protease inhibitors and certain older NRTIs were the strongest drivers; modern integrase inhibitor regimens are far safer metabolically but bring weight gain that itself raises diabetes risk. Metformin remains first-line, with attention to tenofovir kidney effects. Statins, blood-pressure control, and vaccination — including hepatitis B and pneumococcal — are core. HIV testing is reasonable in new diabetes with risk factors, and coordinated infectious disease plus diabetes care delivers the best long-term outcomes.
